Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma

被引：4

作者：

Ansari, Jawaher ^{[1
]}

Hussain, Syed A. ^{[2
]}

Ansari, Asif ^{[3
]}

Glaholm, John ^{[4
]}

机构：

[1] Beatson West Scotland Canc Ctr, 1053 Great Western Rd, Glasgow G12 0YN, Lanark, Scotland

[2] Univ Liverpool, Dept Mol & Clin Canc Med, Liverpool, Merseyside, England

[3] Cleveland Clin, Cleveland, OH 44106 USA

[4] Univ Hosp Birmingham NHS Trust, Birmingham, W Midlands, England

来源：

BIOLOGICS-TARGETS & THERAPY | 2013年 / 7卷

关键词：

metastatic RCC; vascular endothelial growth factor receptor inhibitor; molecular targeted agent; clear-cell carcinoma;

D O I：

10.2147/BTT.S25862

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

A growing understanding of the biology of renal cell carcinoma (RCC) has led to the development and US Food and Drug Administration approval of seven new molecular targeted agents over the past 7 years. Axitinib is a potent, selective, second-generation inhibitor of vascular endothelial growth factor receptors and the latest to join the armamentarium of drugs available for the treatment of metastatic RCC. Despite recent advances in the development of molecular targeted agents for metastatic RCC, the ideal sequencing of these agents remains unclear.

引用

页码：39 / 46

页数：8

共 28 条

[1] Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study
Calvo, E.
Escudier, B.
Motzer, R. J.
Oudard, S.
Hutson, T. E.
Porta, C.
Bracarda, S.
Gruenwald, V.
Thompson, J. A.
Ravaud, A.
Kim, D.
Panneerselvam, A.
Anak, O.
Figlin, R. A.
[J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 (03) : 333 - 339
[2] Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC).
Cella, D.
Escudier, B.
Rini, B. I.
Chen, C.
Bhattacharyya, H.
Tarazi, J. C.
Rosbrook, B.
Kim, S.
Motzer, R. J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[3] Choueiri TK, 2008, CURR OPIN INVEST DR, V9, P658
[4] Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO
[5] 2-#
[6] DUTCHER JP, 2008, J CLIN ONCOL S, V26
[7] Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Escudier, Bernard
Pluzanska, Anna
Koralewski, Piotr
Ravaud, Alain
Bracarda, Sergio
Szczylik, Cezary
Chevreau, Christine
Filipek, Marek
Melichar, Bohuslav
Bajetta, Emilio
Gorbunova, Vera
Bay, Jacques-Olivier
Bodrogi, Istvan
Jagiello-Gruszfeld, Agnieszka
Moore, Nicola
[J]. LANCET, 2007, 370 (9605) : 2103 - 2111
[8] Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
Escudier, Bernard
Bellmunt, Joaquim
Negrier, Sylvie
Bajetta, Emilio
Melichar, Bohuslav
Bracarda, Sergio
Ravaud, Alain
Golding, Sophie
Jethwa, Sangeeta
Sneller, Vesna
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2144 - 2150
[9] Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Escudier, Bernard
Eisen, Tim
Stadler, Walter M.
Szczylik, Cezary
Oudard, Stephane
Staehler, Michael
Negrier, Sylvie
Chevreau, Christine
Desai, Apurva A.
Rolland, Frederic
Demkow, Tomasz
Hutson, Thomas E.
Gore, Martin
Anderson, Sibyl
Hofilena, Gloria
Shan, Minghua
Pena, Carol
Lathia, Chetan
Bukowski, Ronald M.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) : 3312 - 3318
[10] Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, Jacques
Shin, Hai-Rim
Bray, Freddie
Forman, David
Mathers, Colin
Parkin, Donald Maxwell
[J]. INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (12) : 2893 - 2917

← 1 2 3 →